Tuberculosis News and Research RSS Feed - Tuberculosis News and Research

Tuberculosis (TB) is a bacterial infection caused by a germ called Mycobacterium tuberculosis. The bacteria usually attack the lungs, but they can also damage other parts of the body. TB spreads through the air when a person with TB of the lungs or throat coughs, sneezes or talks. If you think you have been exposed, you should go to your doctor for tests as soon as possible. You are more likely to get TB if you have a weak immune system.
NJHF awards 30 grants for NJ researchers working on health-related research

NJHF awards 30 grants for NJ researchers working on health-related research

New Jersey Health Foundation has awarded 30 grants totaling more than $1 million for researchers in New Jersey who are working on health-related research that demonstrates exciting potential. [More]
Indoor air quality in hospitality venues that allow smoking is worse than outdoor, study finds

Indoor air quality in hospitality venues that allow smoking is worse than outdoor, study finds

Research carried out in six cities with dangerous levels of air pollution indicates that air quality inside venues that allow smoking is even worse than outdoors. [More]
Vital Strategies launched to improve global health

Vital Strategies launched to improve global health

A new name in global health - Vital Strategies was launched today, with a mission of reducing disease and premature death and helping to deliver a world where every person has the protection of a strong public health system. [More]

Better universal healthcare needed to reduce CHE for low-income TB patients in China

Improved universal healthcare is urgently needed to lower catastrophic health expenditure (CHE) for low-income tuberculosis (TB) patients in China, according to a study published in the open access journal Infectious Diseases of Poverty. [More]
Johnson & Johnson joins industry-wide call to address growing problem of antimicrobial resistance

Johnson & Johnson joins industry-wide call to address growing problem of antimicrobial resistance

Johnson & Johnson today announced it has joined more than 80 companies and organizations in signing the Declaration on Combating Antimicrobial Resistance (AMR), an industry-wide call to action announced at the World Economic Forum in Davos, Switzerland. [More]
Researchers suggest ways to make TB drugs more efficacious against mutations

Researchers suggest ways to make TB drugs more efficacious against mutations

Biophysicists have discovered why the bacteria that cause tuberculosis (TB) are naturally somewhat resistant to antibiotics known as fluoroquinolones. Their findings, based on mapping the detailed three-dimensional structure of the drugs interacting with an essential enzyme in the TB germ, also reveal why some TB drugs are more potent than others and suggest how drug developers can make fluoroquinolones more efficacious against mutations that make the lung disease drug resistant. [More]
Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Novartis announced today that the US Food and Drug Administration has approved Cosentyx (secukinumab) for two new indications - the treatment of adult patients with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA). [More]
Malaysian scientists join forces with Harvard experts to help revolutionize lung disease treatment

Malaysian scientists join forces with Harvard experts to help revolutionize lung disease treatment

Malaysian scientists are joining forces with Harvard University experts to help revolutionize the treatment of lung diseases -- the delivery of nanomedicine deep into places otherwise impossible to reach. [More]
ISHLT issues new list of criteria to determine patient eligibility for heart transplant

ISHLT issues new list of criteria to determine patient eligibility for heart transplant

To determine patient eligibility for heart transplant, the International Society for Heart Lung Transplantation maintains a list of criteria, first issued in 2006, that acts as a guideline for physicians. [More]
Researchers identify mechanism that allows cancer cells to grow rapidly when blood sugar levels rise

Researchers identify mechanism that allows cancer cells to grow rapidly when blood sugar levels rise

Researchers have identified a mechanism that allows cancer cells to respond and grow rapidly when levels of sugar in the blood rise. This may help to explain why people who develop conditions in which they have chronically high sugar levels in their blood, such as obesity, also have an increased risk of developing certain types of cancer. [More]
International panel of clinical experts comment on state of their fields

International panel of clinical experts comment on state of their fields

In an Editorial published this week in PLOS Medicine, editors ask an international panel of eleven expert researchers and clinicians spanning a range of specialties to answer questions on their field and what developments they hope and expect to see in 2016. [More]
Treating multidrug-resistant tuberculosis with regimens may improve outcomes

Treating multidrug-resistant tuberculosis with regimens may improve outcomes

Treating multidrug-resistant tuberculosis (MDR TB) with regimens that include a greater number of drugs may improve outcomes, and baseline drug susceptibility testing (DST) could identify drugs with the greatest likelihood of success, according to a paper published this week in PLOS Medicine. [More]
NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

Novartis announced today that the results of the MEASURE 1 and MEASURE 2 Phase III studies for Cosentyx® (secukinumab) in ankylosing spondylitis (AS) were published in The New England Journal of Medicine (NEJM). These pivotal studies demonstrated significant clinical improvements with Cosentyx versus placebo in reducing the signs and symptoms of active AS – a long-term, painful and debilitating inflammation of the spine. [More]
Drugs approved for various conditions also have antibiotic properties

Drugs approved for various conditions also have antibiotic properties

A number of drugs already approved to treat parasitic infections, cancers, infertility and other conditions also show promise as antibiotic agents against staph and tuberculosis infections, according to a new study by University of Illinois chemists and collaborators. Because these agents act against multiple targets within the bacteria, it may be harder for bacteria to develop resistance. [More]
ATS commends President Obama for release of National Action Plan to combat TB

ATS commends President Obama for release of National Action Plan to combat TB

The American Thoracic Society applauds President Barack Obama and the Administration for the release of the National Action Plan to Combat Drug Resistant Tuberculosis (TB) today. [More]
New easy-to-use computer program can quickly identify drug-resistant infections

New easy-to-use computer program can quickly identify drug-resistant infections

Scientists have developed an easy-to-use computer program that can quickly analyse bacterial DNA from a patient's infection and predict which antibiotics will work, and which will fail due to drug resistance. The software is currently being trialled in three UK hospitals to see whether it could help speed up diagnosis of drug-resistant infections and enable doctors to better target the prescription of antibiotics. [More]
MPP signs licensing agreement with AbbVie to address future demands for HIV treatment in Africa

MPP signs licensing agreement with AbbVie to address future demands for HIV treatment in Africa

The Medicines Patent Pool today announced a new licensing agreement with AbbVie, a global biopharmaceutical company, that seeks to address future demands for HIV treatment Lopinavir/Ritonavir (LPV/r) in South Africa and across Africa. The agreement has been reached in particular to help ensure sustainability of long-term supply of LPV/r, the most widely used second-line HIV treatment in South Africa and across Africa. [More]
New funding supports research on new and improved drug treatments for tuberculosis, malaria

New funding supports research on new and improved drug treatments for tuberculosis, malaria

University of Toronto and McGill University scientists are leading an international partnership to discover new and improved drug treatments for tuberculosis, malaria and neglected tropical diseases -- thanks to a contribution from Merck Canada Inc., as well as an additional $5 million supplement to a grant from the Bill & Melinda Gates Foundation. [More]
Researchers report development of rapid, low-cost test for detecting TB in resource-limited areas

Researchers report development of rapid, low-cost test for detecting TB in resource-limited areas

Tuberculosis (TB) is a highly infectious disease and a major global health problem, especially in countries with developing health care systems. Because there is no fast, easy way to detect TB, the deadly infection can spread quickly through communities. Now, a team reports in ACS Sensors the development of a rapid, sensitive and low-cost method for detecting the disease in resource-limited areas. [More]
Global Health Impact Index can measure actual impact of drugs worldwide

Global Health Impact Index can measure actual impact of drugs worldwide

Billions of dollars have been spent on developing drugs and supplying them around the world, but which companies' drugs are actually making an impact? The Global Health Impact Index, headed by Binghamton University Associate Professor Nicole Hassoun and highlighted in a new article published Friday in PLOS ONE, addresses this issue by ranking pharmaceutical companies based on their drugs' impact on global health. [More]
Advertisement
Advertisement